Damir Boras
Novo Nordisk
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Damir Boras.
Canadian Journal of Diabetes | 2014
Lawrence A. Leiter; Damir Boras; Vincent Woo
OBJECTIVE Despite their importance in achieving good glycemic control, few real-world data on insulin dosing irregularities and hypoglycemia are available. The multinational, online Global Attitude of Patients and Physicians (GAPP2) survey was conducted to address this situation. METHODS Insulin-treated patients with type 2 diabetes and healthcare professionals (HCPs) who treat such patients were surveyed in an online cross-sectional study. This article summarizes findings from a sample of the online population in a Canadian cohort of 156 patients and 202 HCPs. RESULTS A total of 156 patients completed the questionnaires; 26% reported experiencing a dosing irregularity (missed, mistimed or reduced a basal insulin dose) in the previous 30 days. Up to 60% reported risk for hypoglycemia as the reason for intentional dosing irregularities. Of all patients, 80% reported experiencing a self-treated hypoglycemic event, and 33% recalled having at least 1 event in the previous month. HCPs recorded similar levels of patient-reported dosing irregularities. Over 90% indicated they recommended patients to temporarily reduce their insulin doses to deal with hypoglycemia. CONCLUSIONS A sizeable minority of patients experienced dosing irregularities and self-treated hypoglycemia in this Canadian cohort. The data suggest that HCPs who completed the survey are aware of this and of the need to provide education and support for patients who regularly miss, mistime or reduce insulin doses. Although the desire to prevent hypoglycemic events is understandable and important, HCPs need to ensure fear of hypoglycemia does not compromise optimal diabetes management.
Canadian Journal of Diabetes | 2017
Ronnie Aronson; Ronald Goldenberg; Damir Boras; Rasmus Skovgaard; Harpreet S. Bajaj
OBJECTIVE The true prevalence of hypoglycemia in insulin-treated patients with diabetes and its impact on patients, employers and healthcare providers is poorly appreciated owing to a paucity of real-world data. The global Hypoglycemia Assessment Tool (HAT) study addressed this issue, and here we report data from the Canadian cohort of patients. METHODS This noninterventional, 6-month retrospective and 4-week prospective study enrolled patients aged ≥18 years receiving insulin treatment for >12 months from community endocrinology practices. Data were collected using self-assessment questionnaires and patient diaries. The primary endpoint was the proportion of patients experiencing ≥1 hypoglycemic event during the 4-week prospective observational period. RESULTS Four hundred ninety-eight patients with type 1 diabetes (n=183) and type 2 diabetes (n=315) were enrolled. The prevalence of hypoglycemia was similar in the retrospective (type 1 diabetes, 92.3%; type 2 diabetes, 63.5%) and prospective (type 1 diabetes, 95.2%; type 2 diabetes, 64.2%) periods. Prospective rates of any, nocturnal and severe hypoglycemia per patient-year (95% confidence interval) were 69.3 (66.4; 72.2), 14.2 (12.9; 15.6) and 1.8 [1.4; 2.4]. Higher rates were reported retrospectively, reaching significance for nocturnal hypoglycemia per patient-year (30.0 [28.1; 32.0] vs. 14.2 [12.9; 15.6]; p<0.001). Hypoglycemia led to increased healthcare utilization and absenteeism and was associated with potentially harmful self-care behaviours (e.g., reduced or skipped insulin doses) and increased blood glucose self-monitoring. CONCLUSIONS Prevalence and incidence of hypoglycemia were high among insulin-treated patients with diabetes in Canada, and some patients took harmful or costly actions when they experienced hypoglycemia. Identifying the insulin-treated patients who are at greatest risk may help to reduce the incidence of hypoglycemia.
Canadian Journal of Diabetes | 2012
Tim Heise; Leszek Nosek; Hans-Veit Coester; Carsten Roepstorff; Stine Segel; Nathan Lassota; Damir Boras; Hanne Haahr
Canadian Journal of Diabetes | 2012
Tim Heise; Leszek Nosek; Ulrike Höevelmann; Susanne G. Bøttcher; Hanne Hastrup-Nielsen; Damir Boras; Hanne Haahr
Canadian Journal of Diabetes | 2015
David C.W. Lau; Michel Krempf; Arne Astrup; Carel W. le Roux; Ken Fujioka; Frank L. Greenway; Alfredo Halpern; Rafael Violante Ortiz; John Wilding; Damir Boras; Søren Kruse Lilleøre; Xavier Pi-Sunyer
Canadian Journal of Diabetes | 2015
Sue Pedersen; Ralph A. DeFronzo; Richard M. Bergenstal; Bruce W. Bode; Robert F. Kushner; Andrew Lewin; Maureen Noctor; Damir Boras; Melanie J. Davies
Canadian Journal of Diabetes | 2015
Joanne Liutkus; Ken Fujioka; Arne Astrup; Frank L. Greenway; Alfredo Halpern; Michel Krempf; David C.W. Lau; Carel W. le Roux; Rafael Violante Ortiz; John Wilding; Michael Lyng Wolden; Damir Boras; Xavier Pi-Sunyer
Canadian Journal of Diabetes | 2015
David C.W. Lau; Frank L. Greenway; Ken Fujioka; Arne Astrup; Alfredo Halpern; Michel Krempf; Carel W. le Roux; Rafael Violante Ortiz; John Wilding; Søren Kruse Lilleøre; Damir Boras; Xavier Pi-Sunyer
Canadian Journal of Diabetes | 2015
Adam Blackman; Gary D. Foster; Gary Zammit; Russell Rosenberg; Thomas A. Wadden; Louis J. Aronne; Morten Donsmark; Damir Boras
Canadian Journal of Diabetes | 2016
Damir Boras; Timothy S. Bailey; Róbert Takács; Francisco J. Tinahones; Paturi V. Rao; George M. Tsoukas; Sidsel B. Christensen; Margit Staum Kaltoft; Maximo Maislos